U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07692750) titled 'IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer' on April 26, 2025.
Brief Summary: This is a Phase Ib/II study to evaluate the safety, tolerability and efficacy of IBI343 in combination with chemotherapy in patients with advanced pancreatic cancer, including a Phase Ib safety introduction and Phase II expansion phase.
In phase Ib (safe introduction phase), participants with CLDN18.2-positive advanced pancreatic adenocarcinoma (PAC) who had previously received first-line gemcitabine-based systemic therapy were enrolled to receive IBI343 in combination with chemotherapy.A classic "3+3" dose-escalation design was used ...